Positron emission tomography in the staging and management of breast cancer

British Journal of Surgery

Volumn 91, Issue 11, 2004, Pages 1398-1409

  Byrne, A M ^a   Hill, A D K ^a,b   Skehan, S J ^a   McDermott, E W ^a   O'Higgins, N J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORO 17BETA ESTRADIOL F 18; FLUORODEOXYGLUCOSE F 18; TAMOXIFEN; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER MORTALITY; CANCER STAGING; CARCINOMA IN SITU; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; MALIGNANT TRANSFORMATION; METASTASIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

AXILLA; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 8744300642     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4791     Document Type: Review

References (80)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133-140.
2. Rampaul RS, Pinder SE, Elston CW, Ellis IO. Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. Eur J Surg Oncol 2001; 27: 229-238.
3. Powe JE. Positron emission tomography (PET) scanning in breast cancer. Br J Radiol 1997; 70: 668-670.
4. Rostom AY, Powe J, Kandil A, Ezzat A, Bakheet S, el-Khwsky G et al. Positron emission tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol 1999; 72: 1064-1068.
5. Warburg OH, Dickens F (eds). The Metabolism of Tumours. Richard R Smith: New York, 1931.
6. Smith IC, Welch AE, Chilcott F, Heys SD, Sharp P, Eremin O. Gamma emission imaging in the management of breast disorders. Eur J Surg Oncol 1998; 24: 320-329.
7. Blokland JAK, Trindev P, Stokkel MPM, Pauwels EKJ. Positron emission tomography: a technical introduction for clinicians. Eur J Radiol 2002; 44: 70-75.
8. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-2111.
9. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
10. Som P, Atkins HL, Bandopadhyay D, Fowler JS, MacGregor RR, Matsui K et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): non-toxic tracer for rapid tumour detection. J Nucl Med 1980; 21: 670-675.
11. Wells P, Harte RJA, Price P. Positron emission tomography: a new investigational area for cancer research. Clin Oncol 1996; 8: 7-14.
12. Gutowski TD, Fisher SJ, Moon S, Wahl RL. Experimental studies of 18F-2-deoxy-D-glucose in infection and in reactive lymph nodes. J Nucl Med 1992; 33: 925.
13. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19: 61-77.
14. Greco M, Crippa F, Agresti R. Serengi E, Gerali A, Giovanazzi R et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose- positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001; 93: 630-635.
15. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
16. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
17. 18F-FDG in the lactating breast. J Nucl Med 2001; 42: 1238-1242.
18. Prichard RS, Hill ADK, Skehan S, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002; 89: 389-396.
19. Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T et al. The usefulness of FDG positron emission tomography in the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996; 23: 741-747.
20. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4: 613-620.
21. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227: 319-323.
22. 18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nuc Med 1989; 15: 61-66.
23. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
24. 18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996; 23: 618-623.
25. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonsera TJ, Fusselman MJ et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-1774.
26. Bolster JM, Vaalburg W, Paans AMJ, van Dijk TH, Elsinga PH, Zijlstra JB et al. Carbon-11-labelled tyrosine to study tumor metabolism by positron emission tomography (PET). Eur J Nucl Med 1986; 12: 321-324.
27. 18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989; 13: 1097-1098.
28. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with radiolabeled glucose analogue 2-(F18)-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-770.
29. Nieweg OE, Wong WH, Singletary SE, Hortobagyi GN, Kim EE. Positron emission tomography of glucose metabolism in breast cancer. Potential for tumor detection, staging, and evaluation of chemotherapy. Ann N Y Acad Sci 1993; 698: 423-428.
30. Hoh CK, Hawkins RA, Glaspy JA, Dahlbom M, Tse NY, Huffman EJ et al. Cancer detection with whole-body PET using 2-[18-F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-589.
31. Bruce DM, Evans NT, Heys SD, Needham G, BenYounes H, Mikecz P et al. Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995; 21: 280-283.
32. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996; 37: 931-938.
33. 18-F-FDG be considered as the best method? Int J Oncol 1996; 8: 693-699.
34. Avril N, Dose J, Janicke F, Bense S, Ziegler S, Laubenbacher C et al. Metabolic characteristics of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14: 1848-1857.
35. Noh DY, Yun IJ, Kim JS, Kang HS, Lee DS, Chung JK et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg 1998; 22: 223-228.
36. 18-FDG PET in breast cancer: detection of primary lesions, axillary lymph node metastases, or distant metastases. Clin Pos Imag 2000; 3: 197-205.
37. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18: 3495-3502.
38. Rieber A, Schirrmeister H, Gabelmann A, Nuessle K, Reske S, Kreienberg R et al. Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? Br J Radiol 2002; 75: 789-798.
39. Gopalan D, Bomanji JB, Costa DC, Ell PJ. Nuclear medicine in primary breast cancer imaging. Clin Radiol 2002; 57: 565-574.
40. Crippa F, Agresti R, Seregni E, Greco M, Pascali C, Bogni A et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998; 39: 4-8.
41. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR. Axillary lymph node metastases: Screening with [F-18]2-fluoro-deoxy-2-D-glucose (FDG) PET. Radiology 1997; 203: 323-327.
42. Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W et al. Application of positron emission tomography to cancer screening. Br J Cancer 2000; 83: 1607-1611.
43. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer 1995; 76: 1491-1512.
44. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23: 1588-1593.
45. Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998; 228: 220-227.
46. Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nuessle K et al. Fluorine-182-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28: 351-358.
47. Yang JH, Nam SJ, Lee TS, Lee HK, Jung SH, Kim BT. Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 2001; 31: 1-6.
48. van der Hoeven JJM, Hoekstra OS, Comans EFI, Pijpers R, Boom RP, van Geldere D et al. Determinants of diagnostic performance of [F-18] fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 2002; 236: 619-624.
49. Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 2003; 10: 622-627.
50. Wahl RL, Siegel BA, Coleman RE, Gastsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22: 277-285.
51. Zornoza G, Garcia-Velloso MJ, Sola J, Regueira FM, Pina L, Boerlegui C. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004; 30: 15-19.
52. Ohta M, Tokuda Y, Saitoh Y, Suzuki Y, Okumura A, Kubota M et al. Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer. Breast Cancer 2000; 7: 99-103.
53. Budinger TF. PET instrumentation: what are the limits? Semin Nucl Med 1998; 28: 247-267.
54. Noguchi M. Sentinel lymph node biopsy and breast cancer. Br J Surg 2002; 89: 21-34.
55. Kelemen PR, Lowe V, Phillips N. Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 2002; 3: 73-77.
56. Dose J, Bleckmann C, Bachmann S, Bohuslavizki KH, Berger J, Jenicke L et al. Comparison of fluorodeoxyglucose positron emission tomography and 'conventional diagnostic procedures' for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002; 23: 857-864.
57. Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001; 22: 875-879.
58. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC et al. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002; 128: 325-328.
59. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-3379.
60. Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003; 129: 147-153.
61. Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002; 9: 913-921.
62. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA et al. Randomized trial of chemoendocrine therapy started before or after surgery for the treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-552.
63. Heys SD, Eremin JK, Sarkar TK, Hutcheon AW, Ah-See A, Eremin O. Role of multimodality therapy in the management of locally advanced carcinoma of the breast. J Am Coll Surg 1994; 179: 493-504.
64. 18F]-fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-1695.
65. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
66. Chollet P, Charrier S, Brain E, Cure H, van Praagh I, Feillel V et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997; 33: 862-866.
67. Yang WT, Lam WW, Cheung H, Suen M, King WW, Metreweli C. Sonographic, magnetic resonance imaging, and mammographic assessments of preoperative size of breast cancer. J Ultrasound Med 1997; 16: 791-797.
68. Helvie MA, Joynt LK, Cody RL, Pierce LJ, Adler DD, Merajver SD. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 1996; 198: 327-332.
69. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18: 1676-1688.
70. 18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002; 38: 375-379.
71. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 2001; 42: 1334-1337.
72. Mortimer JE, Dehdashti F, Siegel BA, Trinkhaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19: 2797-2803.
73. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 1993; 71: 1266-1272.
74. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase II trials. J Clin Oncol 1996; 14: 2000-2011.
75. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of 'metabolic flare' to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999; 26: 51-56.
76. van Dongan JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D et al. Long term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization of Research and Treatment of Cancer 10 801 trial. J Natl Cancer Inst 2000; 92: 1143-1150.
77. Molina R, Zanon G, Fiella X, Moreno F, Jo J, Daniels M et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36: 41-48.
78. 18F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 2002; 32: 244-247.
79. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 1996; 17: 197-198.
80. Ahmad A, Barrington S, Maisey M, Rubens RD. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999; 79: 478-482.